Rocket Pharmaceuticals (RCKT) Earnings Date & Reports

Key Takeaways

• Analysts expect Rocket Pharmaceuticals to report EPS of -$0.41 for Q1 2026, improving from -$0.56 in Q1 2025.
• No consensus revenue estimate available, consistent with the company's pre-commercial stage and $0 revenue in recent quarters.
• Cash position stood at $188.9 million as of December 31, 2025, funding operations into Q2 2027.
• Key focus: Updates on RP-A501 Phase 2 trial resumption for Danon disease in H1 2026 and KRESLADI™ PDUFA on March 28, 2026.
• Recent Q4 2025 EPS beat consensus by $0.04 at -$0.38 versus -$0.42 expected.
• Pipeline prioritization on AAV cardiovascular programs amid cost controls.

Earnings Context and Why It Matters

Rocket Pharmaceuticals (RCKT), a late-stage biotech developing gene therapies for rare disorders, operates in a high-stakes environment where clinical milestones drive value. With no approved products yet generating revenue, investors scrutinize cash burn, expense management, and pipeline progress. The Q1 2026 report, due in early May, follows a Q4 2025 where net loss narrowed to $42.5 million from $60.3 million year-over-year, aided by 17% R&D and 15% G&A expense cuts. Amid FDA decisions like KRESLADI™ for severe LAD-I (leukocyte adhesion deficiency-I), this earnings will signal financial health and execution on cardiovascular gene therapy focus, critical for sustaining runway and unlocking shareholder value in a competitive rare disease space.

Earnings Expectations

Consensus calls for an EPS loss of -$0.41 for the first quarter ended March 31, 2026, based on input from three analysts, an improvement from the prior year's -$0.56. Revenue expectations are absent due to the company's development-stage status, with $0 reported across recent quarters. Investors will watch R&D spend trends after full-year 2025's $142 million (down 17% YoY) and G&A at $86.5 million (down 15%). Historical beats, like Q4's -$0.38 versus -$0.42 expected, suggest potential for outperformance via cost discipline. Key metrics include cash updates from $188.9 million at year-end and pipeline catalysts, such as RP-A501 dosing resumption and RP-A701 Phase 1 start mid-2026. Stock has reacted positively to beats historically, rising 10.6% the day after Q4 release.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.

Market Reaction and Investor Sentiment

Heading into Q1 earnings, sentiment is cautious yet optimistic, buoyed by Q4's EPS beat and pipeline momentum but tempered by biotech sector volatility and recent stock declines post-FDA approval news. Shares surged 10.6% the day after Q4 results on February 27, 2026, reflecting approval for narrower losses and clinical updates. Key risks include clinical hold resolutions, regulatory timelines, and cash burn exceeding expectations. Historically, RCKT moves average 1.8% up post-earnings on beats, underscoring sensitivity to execution signals.

Forward Outlook and Key Factors to Monitor

Post-Q1, attention shifts to near-term catalysts shaping Rocket's trajectory. The PDUFA date for KRESLADI™ on March 28, 2026, looms large; approval could yield a Priority Review Voucher worth up to $200 million non-dilutive cash, extending runway beyond Q2 2027.

Pipeline execution remains pivotal. Monitor updates on RP-A501 (Danon disease), with Phase 2 dosing resuming H1 2026 at adjusted 3.8 × 10¹³ GC/kg dose under FDA agreement. Progress in RP-A601 (PKP2-ACM) Phase 1 enrollment and RP-A701 (BAG3-DCM) Phase 1 startup mid-2026 will gauge cardiovascular platform momentum.

Financially, track cash versus $188.9 million year-end, R&D efficiency post-17% cut, and any restructuring impacts. Broader dynamics like gene therapy competition and manufacturing scalability at Cranbury facility warrant scrutiny. Balanced cost control and milestone hits will define path to potential commercialization.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations